
    
      A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and
      antiviral activity of the combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and
      ABT-333 with and without ribavirin (RBV) in treatment-naive, noncirrhotic participants with
      chronic hepatitis C virus genotype 1a (HCV GT1a) infection.
    
  